This review examines the mechanisms by which GLP-1 receptor agonists confer health benefits beyond weight loss, including effects on cardiovascular, renal, hepatic, musculoskeletal, and overall organismal health via neural circuits, immune pathways, inter-organ communication, and local GLP-1 receptor engagement.
GLP-1R agonism exerts broad efficacy through weight-loss-independent mechanisms — recruiting neural and immune circuits and engaging local GLP-1Rs across multiple organ systems — suggesting therapeutic potential that extends well beyond glycemic control or weight reduction.
As a review/perspective article, no primary trial data or patient-level outcomes are reported; dose-response relationships for weight-loss-independent mechanisms are described as not yet well defined.
Clinicians should recognize that GLP-1 medicines may benefit cardiovascular, renal, and hepatic health through direct organ-level actions, not solely via weight loss. This supports their use in patients who may not achieve substantial weight reduction but still stand to gain organ-protective benefits.
Explore related topics
